- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04888364
French Parkinson's Disease Cohort - NS-PARK (NS-PARK)
Cohort of the French Clinical Research Network for Parkinson's Disease (NS-PARK Cohort)
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
The national clinical research network for Parkinson's disease (NS-PARK/FCRIN) reassembles all expert centers in Parkinson's disease (PD) in France. Its aim is to promote clinical research in Parkinson's disease and movement disorder, to better understand the pathophysiology of PD, foster the development of new therapeutic strategies, and move towards personalized medicine. To help centers for prescreening, a national registry of PD patients followed in each centers has been implemented in 2016 to collect minimal relevant clinical information of patients followed in each center including demographic data, age at diagnosis, standardized motor and non-motor symptoms evaluation, and treatment. Data are updated at each visit of the patient in the center. De facto, this registry became a longitudinal cohort of PD patients followed in NS-PARK centers. In 2020, NS-PARK received funding to associate a biocollection to this clinical cohort.
The aim of NS-PARK cohort are to describe the natural history of PD progression in clinical routine in France, to develop new models of PD describing the different progression profiles, and to propose patients stratification based on PD pathophysiological mechanisms. The cohort will also serve as a platform to discover new PD genes and genetic modifiers of disease progression or response to treatment.
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studiekontakt
- Namn: Jean Christophe MD CORVOL, PU-PH
- Telefonnummer: 33 1 42 16 57 66
- E-post: jean-christophe.corvol@aphp.fr
Studieorter
-
-
-
Paris, Frankrike, 75013
- Rekrytering
- Centre 01 Paris
-
Kontakt:
- Jean Christophe MD Corvol, Pr
- Telefonnummer: 33 1 42 16 57 66
- E-post: jean-christophe.corvol@aphp.fr
-
Huvudutredare:
- Jean Christophe MD Corvol, Pr
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Diagnosis of Parkinson's disease according to UK PD brain bak criteria
- OR diagnosis of parkinsonian syndrome: multiple system atrophy, progressive supranuclear palsy, dementia with Lewy body, or corticobasal syndrom
- OR Subjects at risk of PD defined as :
No symptom or diagnosis of Parkinson's disease nor parkinsonian syndrome, and relative to a patient with a diagosis of PD or parkinsonian syndrome, or carrier of a known mutation responsible for a genetic form of PD or patient with a diagnosis of idiopathic REEM sleep disorder or prodromal form of PD as defined by MDS criteria (Berg et al., 2015)
AND for all participants
- Affiliated to social security
- Age > 10 years
Exclusion Criteria:
- Subject under legal protection
- Subject who do not consent to the research
- for the optional skin biopsy only: clinically significant coagulation abnormalities or anticoagulant treatment
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Disease progression
Tidsram: through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Hoehn and Yahr score change
|
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Motor and non-motor complications
Tidsram: through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Occurence of motor (dyskinesia or motor fluctuations) or non-motor (dementia, dysautonomia, behavioral or psychiatric disorders, sleep disorders, falls, ...) complication
|
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Modification of antiparkinsonian treatment doses
Tidsram: through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Modification of antiparkinsonian treatment during follow-up will be measured as levodopa equivalent daily doses
|
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Predictive factorsof PD progression: motor or non motor symptoms
Tidsram: through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Motor or non motor symptoms as measured by MDS-UPDRS scores will be used as predictive factors for primary outcomes
|
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Predictive factors of PD progression: genetic variants
Tidsram: through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Genetic variants in PD genes or the Genetic PD risk score will be used as predictive factors for primary outcomes.
|
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Predictive factors of PD progression: brain imaging markers
Tidsram: through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Brain imaging makers (iron or neuromelanine content of the substantia nigra) will be used as predictive factors for primary outcomes
|
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Clusters of patients with similar disease progression profiles
Tidsram: through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Clustering analyses will be performed on disease progression markers (Hoehn and Yahr score, MDS-UPDRS scores, and doses of treatment (levodopa equivalent daily doses)) to identify homogeneous groups of patients (clusters) sharing similar disease progression profiles.
|
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Clusters of patients with similar genetic and disease progression profiles
Tidsram: through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Co-clustering analysis of disease progression markers (Hoehn and Yahr score, MDS-UPDRS scores, and doses of treatment (levodopa equivalent daily doses)) and genetic markers (variants in PD genes or the Genetic PD risk score).
|
through the end of follow-up in the cohort, at least 2 years, and average of 5 years
|
Genetic mutations associated with familal forms of PD
Tidsram: through study completion, 15 years
|
Genetic mutations will be screened by different methods (gene panels, whole exome or whole genome) in familial forms of PD.
Mutations co-segregated with PD will be considered as potentially associated with the disease.
|
through study completion, 15 years
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Jean Christophe MD CORVOL, PU-PH, UMRS 1127
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- C16-56
- 2019-A01929-48 (Registeridentifierare: RCB ID)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Parkinsons sjukdom
-
Abbott Medical DevicesBaylor College of Medicine; University of HoustonAvslutad
-
Bial - Portela C S.A.Avslutad
-
Mayo ClinicAvslutad
-
Ataturk UniversityRekrytering
-
Centre Hospitalier Universitaire, AmiensOkändParkinson | ImpulskontrollstörningFrankrike
-
University of Sao Paulo General HospitalInCor Heart InstituteAvslutadHjärtarytmier | Tillbehörsväg | Wolf Parkinson White SyndromeBrasilien
-
Institute for Neurodegenerative DisordersAvslutadParkinson | Parkinsons syndromFörenta staterna
-
Assistance Publique - Hôpitaux de ParisCentre Hospitalier Universitaire de Pointe-a-PitreAvslutad
-
University of PlymouthHar inte rekryterat ännu
-
Massachusetts General HospitalAnmälan via inbjudanParkinsons sjukdom | ParkinsonFörenta staterna